Delivery Order SPE2DB20D2014-SPE2DB25FD08T
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,957.42 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This non-competitive delivery order, with a firm fixed price structure, represents a child contract against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $44,107.24 under firm fixed-price terms. The contract, which is classified as a child order under a larger indefinite delivery vehicle, requires completion by July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL syringes valued at $4,991.39. This non-set-aside, firm fixed-price delivery order is scheduled for completion by July 28, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a discrete purchase under AmerisourceBergen's existing contract vehicle with the DLA. AmerisourceBergen Drug Corp is a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $32,376.84 under a firm fixed-price contract type. The delivery order, which represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), is to be fulfilled from the company's Conshohocken, Pennsylvania facility....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes valued at $12,767.10, with completion scheduled for September 24, 2025. This competitively awarded, firm fixed-price delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. The award was issued to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $47,704.56 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 8, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $4,970.25 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on June 18, 2025, with an ultimate completion date of June 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery transaction under AmerisourceBergen's existing pharmaceutical supply framework. The place of performance is listed as Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $57,859.44 under a Firm Fixed Price contract type. This is a non-set-aside award, reflecting AmerisourceBergen's demonstrated capability to compete for federal pharmaceutical procurement requirements. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $24,419.18 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Dupixent 300 mg/2 ml syringes and has a completion date of February 3, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $15,257.22 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of July 15, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will fulfill this order from its corporate office location. This delivery order falls...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FD08TDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $7,190.64. The contract was awarded on September 23, 2025, with an ultimate completion date of September 24, 2025, utilizing firm fixed pricing with no set-aside designation. This delivery order represents a competitively awarded transaction under AmerisourceBergen's existing federal contract vehicle with the DLA. This award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The IDC serves as a comprehensive pharmaceutical supply vehicle enabling AmerisourceBergen to deliver a broad range of medications and medical supplies to support military healthcare programs globally. AmerisourceBergen's federal contract portfolio demonstrates significant capability in fulfilling Defense Health Agency and federal medical procurement requirements across multiple therapeutic domains, making it a critical vendor within the military medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 9/23/25 |